Amygdalin attenuates post-ischemic neuroinflammation by targeting TLR4/NF-κB signaling and NLRP3 inflammasome in cerebral ischemia-reperfusion injury.

Researchers investigated whether amygdalin, a natural compound found in bitter almonds and apricot kernels, could protect brain cells after stroke. Stroke occurs when blood flow to the brain is blocked, and ironically, restoring blood flow can sometimes cause additional damage through inflammation. This study used rat models of stroke and laboratory cell cultures to test amygdalin's protective effects.

The researchers found that amygdalin significantly reduced brain inflammation and improved neurological function after stroke. It worked by blocking specific inflammatory pathways in the brain, particularly targeting immune cells called microglia that can become overactive and damage healthy tissue. Amygdalin helped shift these cells from a harmful inflammatory state to a protective, healing state. It also reduced oxidative stress and prevented a destructive form of cell death called pyroptosis.

Using advanced genetic and metabolic analysis combined with molecular testing, the team identified exactly how amygdalin works: it inhibits the TLR4/NF-κB/NLRP3 signaling pathway, which is a key driver of post-stroke inflammation. When they combined amygdalin with drugs that block the same pathway, there was no additional benefit, confirming this was the main mechanism of action.

For patients considering complementary approaches to stroke recovery, this research suggests that herbal compounds targeting inflammation may have therapeutic potential. While amygdalin showed promise in this laboratory study, human clinical trials are needed before it can be recommended as a treatment. Traditional Chinese Medicine practitioners sometimes use herbs containing amygdalin-related compounds as part of comprehensive treatment protocols. If you're interested in herbal medicine approaches for stroke recovery or prevention, consult with a qualified, licensed acupuncturist or TCM practitioner who can develop an individualized treatment plan.

This preclinical study investigated amygdalin's neuroprotective mechanisms in cerebral ischemia-reperfusion injury using rat MCAO/R models and BV-2 microglial cell OGD/R models. Multi-omics analysis (transcriptomics and untargeted metabolomics) combined with molecular docking identified the TLR4/NF-κB/NLRP3 inflammasome axis as the primary therapeutic target. Amygdalin significantly improved neurological function, reduced infarct volume, and attenuated post-ischemic inflammation and oxidative stress. Mechanistically, it suppressed M1 microglial polarization while promoting M2 phenotypes, reduced pyroptosis markers (NLRP3, caspase-1, GSDMD), and decreased pro-inflammatory cytokine release. Pharmacological dissection using TAK-242 (TLR4 inhibitor) and MCC950 (NLRP3 inhibitor) revealed no synergistic effects when combined with amygdalin, confirming pathway specificity. Key molecular targets included Tlr4, Myd88, Nlrp3, and Caspase-1. Clinical relevance: This provides mechanistic evidence for amygdalin-containing herbal formulas in stroke management, supporting traditional uses of Prunus species in TCM neurology protocols. Human trials are needed to establish dosing and safety parameters.